[{"orgOrder":0,"company":"University Hospital, Lille","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Vismodegib","moa":"Smoothened homolog","graph1":"Oncology","graph2":"Phase II","graph3":"University Hospital, Lille","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Lille \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital, Lille \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Vismodegib","moa":"Smoothened homolog","graph1":"Undisclosed","graph2":"Phase I","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital, Lille","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vismodegib","moa":"Smoothened homolog","graph1":"Oncology","graph2":"Phase II","graph3":"University Hospital, Lille","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Lille \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital, Lille \/ Sun Pharmaceutical Industries Limited"},{"orgOrder":0,"company":"Lymphoma Academic Research Organisation","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Vismodegib","moa":"Smoothened homolog","graph1":"Oncology","graph2":"Phase II","graph3":"Lymphoma Academic Research Organisation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lymphoma Academic Research Organisation \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Lymphoma Academic Research Organisation \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"SRH Wald-Klinikum Gera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Vismodegib","moa":"Smoothened homolog","graph1":"Oncology","graph2":"Phase II","graph3":"SRH Wald-Klinikum Gera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SRH Wald-Klinikum Gera \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SRH Wald-Klinikum Gera \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vismodegib","moa":"Smoothened homolog","graph1":"Oncology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Vismodegib","moa":"Smoothened homolog","graph1":"Oncology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Vismodegib","moa":"Smoothened homolog","graph1":"Oncology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Vismodegib","moa":"Smoothened homolog","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"University of Arizona","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Vismodegib","moa":"Smoothened homolog","graph1":"Oncology","graph2":"Phase I","graph3":"University of Arizona","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Arizona \/ Genentech","highestDevelopmentStatusID":"6","companyTruncated":"University of Arizona \/ Genentech"},{"orgOrder":0,"company":"UCSF Benioff Children's Hospital Oakland","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Vismodegib","moa":"Smoothened homolog","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"UCSF Benioff Children's Hospital Oakland","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UCSF Benioff Children's Hospital Oakland \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"UCSF Benioff Children's Hospital Oakland \/ Genentech"},{"orgOrder":0,"company":"Alliance for Clinical Trials in Oncology","sponsor":"National Cancer Institute | GSK | Genentech | Brain Science Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Vismodegib","moa":"Smoothened homolog","graph1":"Oncology","graph2":"Phase II","graph3":"Alliance for Clinical Trials in Oncology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alliance for Clinical Trials in Oncology \/ National Cancer Institute | GSK | Genentech | Brain Science Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Alliance for Clinical Trials in Oncology \/ National Cancer Institute | GSK | Genentech | Brain Science Foundation"},{"orgOrder":0,"company":"NYU College of Dentistry","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Vismodegib","moa":"Smoothened homolog","graph1":"Oncology","graph2":"Phase II","graph3":"NYU College of Dentistry","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NYU College of Dentistry \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"NYU College of Dentistry \/ Genentech"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Vismodegib","moa":"Smoothened homolog","graph1":"Oncology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Vismodegib","moa":"Smoothened homolog","graph1":"Oncology","graph2":"Phase I","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Vismodegib","moa":"Smoothened homolog","graph1":"Oncology","graph2":"Phase I","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Moffitt Cancer Center","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vismodegib","moa":"Smoothened homolog","graph1":"Oncology","graph2":"Phase I","graph3":"Moffitt Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Moffitt Cancer Center \/ Genentech","highestDevelopmentStatusID":"6","companyTruncated":"Moffitt Cancer Center \/ Genentech"},{"orgOrder":0,"company":"Genentech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Vismodegib","moa":"Smoothened homolog","graph1":"Oncology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Genentech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Undisclosed"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Vismodegib","moa":"Smoothened homolog","graph1":"Oncology","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ Genentech"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Vismodegib","moa":"Smoothened homolog","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"National Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Cancer Institute \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"National Cancer Institute \/ Genentech"},{"orgOrder":0,"company":"Stamford Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SP-002","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Stamford Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Stamford Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Stamford Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Lisa Bax","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Vismodegib","moa":"Smoothened homolog","graph1":"Oncology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"F. Hoffmann-La Roche \/ Lisa Bax","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Lisa Bax"},{"orgOrder":0,"company":"Genentech","sponsor":"Sue Yom","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Vismodegib","moa":"Smoothened homolog","graph1":"Oncology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Sue Yom","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Sue Yom"},{"orgOrder":0,"company":"Genentech","sponsor":"Ronald Buckanovich","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vismodegib","moa":"Smoothened homolog","graph1":"Oncology","graph2":"Phase II","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Ronald Buckanovich","highestDevelopmentStatusID":"8","companyTruncated":"Genentech \/ Ronald Buckanovich"}]

Find Clinical Drug Pipeline Developments & Deals for Vismodegib

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : SP-002 is an adenovirus-based biologic producing Interferon-g, under investigation with vismodegib for locally advanced metastatic basal cell carcinoma.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 11, 2024

                          Lead Product(s) : SP-002,Vismodegib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : Vismodegib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Basal Cell.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 15, 2022

                          Lead Product(s) : Vismodegib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Genentech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          University Hospital, Lille

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          University Hospital, Lille

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          Details : Vismodegib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Basal Cell.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 30, 2022

                          Lead Product(s) : Vismodegib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Sun Pharmaceutical Industries Limited

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : Vismodegib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Fallopian Tube Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 13, 2022

                          Lead Product(s) : Vismodegib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Ronald Buckanovich

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          SRH Wald-Klinikum Gera

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          SRH Wald-Klinikum Gera

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          Details : Vismodegib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Basal Cell.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 27, 2017

                          Lead Product(s) : Vismodegib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          University Hospital, Lille

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          University Hospital, Lille

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          Details : Erivedge is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Basal Cell.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 29, 2016

                          Lead Product(s) : Vismodegib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : F. Hoffmann-La Roche

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          University of Arizona

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          University of Arizona

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          Details : Vismodegib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Basal Cell.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 24, 2015

                          Lead Product(s) : Vismodegib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Genentech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Alliance for Clinical Trials in Oncology

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          Alliance for Clinical Trials in Oncology

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          Lead Product(s) : Vismodegib

                          Therapeutic Area : Oncology

                          Study Phase : Phase II

                          Sponsor : National Cancer Institute | GSK | Genentech | Brain Science Foundation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Vismodegib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Meningioma.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 14, 2015

                          Lead Product(s) : Vismodegib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : National Cancer Institute | GSK | Genentech | Brain Science Foundation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          NYU College of Dentistry

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          NYU College of Dentistry

                          Country arrow
                          SupplySide West
                          Not Confirmed

                          Details : Vismodegib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Odontogenic Tumors.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 19, 2015

                          Lead Product(s) : Vismodegib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Genentech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          SupplySide West
                          Not Confirmed
                          SupplySide West
                          Not Confirmed

                          Details : Vismodegib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Bronchiolitis Obliterans Syndrome.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 13, 2015

                          Lead Product(s) : Vismodegib

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Genentech

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank